Latest News

Amgen to stop selling Repatha at higher list price, offer low-priced option exclusively

heart, doctor, cardiac

The biotech company had kept the drug available at the higher list price in order to give payers and pharmacy benefit managers time to adjust contracts and minimize supply chain disruptions.

Source link

Related posts

New Model Shows COVID More Widespread, Less Severe


Medical News Today: Eating dinner earlier could reduce cancer risk


Broad and Effective Protection against Staphylococcus aureus Is Elicited by a Multivalent Vaccine Formulated with Novel Antigens


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy